In this report, Technavio covers the present scenario and the growth prospects of the global venous thromboembolism (VTE) market for the period 2017-2021 (base year-2016). To calculate the market size, we consider revenue generated from the sales of VTE products in the following drug classes:Factor Xa inhibitors,Direct thrombin inhibitors,Heparin,Vitamin K antagonists.

PART 01: Executive summary 6

PART 02: Scope of the report 17

Market overview 17

Top-vendor offerings 18

PART 03: Market research methodology 19

Research methodology 19

Economic indicators 19

PART 04: Introduction 20

Key market highlights 20

Highlights 20

PART 05: Disease overview 22

Diagnosis of VTE 22

Treatment of VTE 22

PART 06: Pipeline analysis 23

PART 07: Market landscape 25

Market overview 25

Five forces analysis 28

PART 08: Market segmentation by drug class 29

Factor Xa inhibitors 29

Direct thrombin inhibitors 30

Heparin 32

Vitamin K antagonists 34

PART 09: Geographical segmentation 36

VTE therapeutics market in Americas 37

VTE therapeutics market in EMEA 39

VTE therapeutics market in APAC 41

PART 10: Market drivers 43

Increasing adoption of NOACs 43

Increasing surgical procedures such as hip and knee

replacements 43

Large patient pool coupled with growing awareness

campaigns 44

PART 11: Impact of drivers 46

PART 12: Market challenges 47

Presence of alternatives such as thrombectomy and

percutaneous techniques 47

Unmet needs for anticoagulant reversal agents 47

Extensive use of generic products 48

PART 13: Impact of drivers and challenges 50

PART 14: Market trends 51

Development of drugs for new indications 51

Growing focus on emerging economies 52

Patient assistance programs 53

PART 15: Vendor landscape 54

Competitive scenario 54

PART 16: Key vendor analysis 59

Bayer HealthCare 59

BMS 62

Boehringer Ingelheim 66

Daiichi Sankyo 69

Johnson & Johnson 72

Sanofi 75

Other prominent vendors 78

PART 17: Appendix 80

List of abbreviations 80

PART 18: Explore Technavio 81